Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 921 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCD Clear all

Conditions: Sickle Cell Disease, Acute Chest Syndrome
Interventions: Defibrotide; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 2 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Sickle Cell Disease
Interventions: Etavopivat; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy, Sirolimus; Drug · Procedure · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 12 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Duarte, California

Conditions: Diagnoses Disease
Interventions: HemoTypeSC; Device
Lead sponsor: Silver Lake Research Corporation; Industry
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Azusa, California

Conditions: Sickle Cell Disease
Interventions: Music therapy, Health education; Behavioral · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 14 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Cleveland, Ohio • Greenville, South Carolina

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 4
States / cities: Atlanta, Georgia • Louisville, Kentucky • Bethesda, Maryland + 1 more

Conditions: Anemia, Sickle Cell, Healthy Volunteers
Interventions: BMS-986470, Placebo, Famotidine, Pantoprazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • La Jolla, California • Oakland, California + 14 more

Conditions: Spontaneous Coronary Artery Dissection
Interventions: Not listed
Lead sponsor: SCAD Alliance; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 30
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 24 more

Conditions: Sudden Cardiac Arrest
Interventions: HeartStart HS1; Device
Lead sponsor: Heartstream US LLC; Industry
Eligibility: Not listed
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Sickle Cell Disease, Diabetes Mellitus
Interventions: Not listed
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anemia, Sickle Cell
Interventions: Rivipansel, Placebo; Drug · Other
Lead sponsor: Biossil Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 126
States / cities: Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more

Conditions: Sickle Cell Disease
Interventions: AB1; Drug
Lead sponsor: Nirmish Shah; Other
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina

Conditions: Sickle Cell Disease
Interventions: Dronabinol 2.5 MG, Microcrystalline cellulose; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Death, Sudden, Cardiac, Ventricular Fibrillation, Tachycardia, Atrial Fibrillation, Sick Sinus Syndrome
Interventions: Not listed
Lead sponsor: Medtronic Corporate Technologies and New Ventures; Industry
Eligibility: 40 Years and older
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Sickle Cell Anemia, Sickle Cell Thalassemia, Sickle Cell Pain, Hbss, Hbsc, Sickle Beta Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Syndrome Variant
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 16 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions: Montelukast added to Hydroxyurea, Placebo added to Hydroxyurea; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 16 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Nashville, Tennessee • Milwaukee, Wisconsin

Conditions: Sickle Cell Disease, Chronic Pain
Interventions: Quantitative sensory testing; Other
Lead sponsor: Duke University; Other
Eligibility: 15 Years to 40 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Benign and Malignant Hematologic Diseases
Interventions: Protease Inhibitors; Combination Product
Lead sponsor: American Society of Hematology; Other
Eligibility: 1 Year to 65 Years
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Anemia, Sickle Cell
Interventions: Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease
Interventions: FDNIRS-DCS, MRI; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
Interventions: CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea, Rituximab, Alemtuzumab, Fludarabine, Thiotepa; Biological · Drug
Lead sponsor: Paul Szabolcs; Other
Eligibility: 5 Years to 40 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pulmonary Hypertension, Sickle Cell Disease, Thalassemia
Interventions: L-Glutamine; Drug
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 4 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Oakland, California

Conditions: Neuropathic Pain, Sickle Cell Disease
Interventions: Eight Percent Topical Capsaicin; Drug
Lead sponsor: Children's Hospital of Michigan; Other
Eligibility: 14 Years to 21 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Sickle Cell Disease
Interventions: Guided Imagery; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 13 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings

MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease

Screening Patients With Sickle Cell Disease for Kidney Damage

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

HeartStart HS1 Defibrillator* Event Registry

Glucose Metabolism in Sickle Cell Disease

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

AB1 in Adult Patients With Sickle Cell Disease (SCD)

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

Medtronic Genetic Arrhythmia Markers for Early Detection (GAME Study)

Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia

Predictors of Pain in Sickle Cell Disease

The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

Siplizumab for Sickle Cell Disease Transplant

A Pilot Study on Neuroimaging in SCD: Part of The Boston Consortium to Cure Sickle Cell Disease

T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias

Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

Sickle Cell Pain: Intervention With Capsaicin Exposure

A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease